March 17, 2014
Marlborough biotech: Good test results for diabetes drug
By Rick Saia
A Marlborough biotech company is reporting positive results from the second phase of a test for a drug intended to treat Type 2 diabetes.
Theracos Inc. said the 96-week study, which involved 288 subjects with the disease from the U.S., Mexico and Colombia evaluated the effectiveness of its THR1442 drug, which is a sodium-glucose co-transporter 2, or SGLT2.
CEO 'extremely pleased'
“We are extremely pleased with the results of this study” said company president and CEO Albert Collinson.
Theracos, Inc. is a privately held pharmaceutical research and development company founded in 2000. It’s engaged in the discovery and development of new therapies designed to treat in areas of unmet medical need.
Image source: Freedigitalphotos.net
WBJ Web Partners
Most Recent
Most Recent
0 Comments